dpp 4 inhibitor glp 1 agonist DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits GLP-1 receptor agonists or DPP-4
Description
The ease of administration and long-term management of diabetes and obesity with oral GLP-1 receptor agonist is driving their widespread adoption
It may be delivered through patches, gels, sprays, or oral formulations
Collectively, these advancements are reshaping treatment protocols and boosting the role of GLP-1 therapies in chronic disease management
Safety considerations: The FDA continues to crack down on compounded (non-FDA-approved) semaglutide and tirzepatide products due to serious safety reports tied to misdosing and sterility issues
Parkinsons disease and enhanced inflammatory response
